Table 1 Characteristics of the patients
Characteristic | Total (n = 38) |
|---|---|
Age (years) | 59.4 ± 9.2 |
Median (range) | 60 (35, 79) |
Sex, n (%) | |
Male | 32 (84.2) |
Female | 6 (15.8) |
ECOG performance status, n (%) | |
0 | 20 (52.6) |
1 | 13 (34.2) |
2 | 5 (13.2) |
BCLC grade, n (%) | |
B | 18 (47.4) |
C | 20 (52.6) |
Hepatitis, n (%) | |
Hepatitis B | 32 (84.2) |
Hepatitis C | 2 (5.3) |
No | 4 (10.5) |
Maximum tumor size (cm) | 3.75 (0.9, 15.1) |
Tumor number, n (%) | |
Single | 4 (10.5) |
Multiple | 32 (84.2) |
Unknown | 2 (5.3) |
Child–Pugh grade, n (%) | |
A | 37 (97.4) |
B | 1 (2.6) |
Macrovascular invasion, n (%) | 12 (31.6) |
AFP ≥ 400 μg/L, n (%) | 11 (28.9) |
Comorbidity, n (%) | |
Hypertension | 15 (39.5) |
Diabetes Mellitus | 4 (10.5) |
Extrahepatic metastasis, n (%) | 13 (34.2) |
Prior local therapy, n (%) | |
Surgery | 13 (34.2) |
Ablation | 20 (52.6) |
TACE | 36 (94.7) |
Radiotherapy | 6 (15.8) |
Prior systemic therapy, n (%) | |
Sorafenib | 33 (86.8) |
Lenvatinib | 1 (2.6) |
Lenvatinib sequential to sorafenib | 4 (10.5) |
Follow-up (months), median (range) | 5.6 (0.7, 17.0) |